Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Philogen SpA ( (IT:PHIL) ) has shared an announcement.
Philogen S.p.A. has announced its corporate event calendar for 2025, detailing key dates for the approval of various financial reports and shareholder meetings. This announcement is significant for stakeholders as it outlines the timeline for financial performance disclosures and progress updates on key trials, providing insights into the company’s operational and strategic directions.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of targeted anti-cancer drugs. The company uses proprietary technologies to discover and develop pharmaceutical products that deliver potent therapeutic agents directly to tumor masses while sparing healthy tissues. Philogen’s innovative approach, known as tumor targeting, aims to treat diseases with high mortality rates, primarily focusing on oncological applications, but also potentially applicable to other diseases.
YTD Price Performance: -1.32%
Average Trading Volume: 268
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €520.5M
See more insights into PHIL stock on TipRanks’ Stock Analysis page.
